Increased expression of class III β-tubulin in castration-resistant human prostate cancer

Ixabepilone: targeting  III-tubulin expression in taxane-resistant malignancies

(2009) C. Dumontet et al.   MOLECULAR CANCER THERAPEUTICS

β3-Tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway

(2009) Jennifer Saussede-Aim et al.   CELL MOTILITY AND THE CYTOSKELETON

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Class III  -Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel

(2008) C. M. Galmarini et al.   CLINICAL CANCER RESEARCH

Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression

(2008) S Azoulay et al.   JOURNAL OF PATHOLOGY

Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer

(2008) Sunita R. Setlur et al.   JNCI-Journal of the National Cancer Institute

Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?

(2008) Pascal Sève et al.   LANCET ONCOLOGY

Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation

(2008) D. E. Frigo et al.   MOLECULAR CANCER THERAPEUTICS

Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors

(2008) E. Rivera et al.   ONCOLOGIST

Hypoxia induces class III beta-tubulin gene expression by HIF-1α binding to its 3' flanking region

(2007) Giuseppina Raspaglio et al.   GENE